Market Research Logo

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)
  • The report reviews Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Overview
Therapeutics Development
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Stage of Development
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Therapy Area
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Indication
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Companies
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Companies Involved in Therapeutics Development
Crescendo Biologics Limited
Exicure, Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Vipergen ApS
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Drug Profiles
Antisense Oligonucleotide to Antagonize IL-17RA for Inflammatory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimekizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-34935 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-35018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-35762 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-36041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit IL-17A for Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize IL-17A for Inflammatory and Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Dormant Projects
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Featured News & Press Releases
Jun 10, 2016: UCB’s bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis
Jun 08, 2016: UCB presents Phase 1b data on Bimekizumab at the Annual European Congress of Rheumatology (EULAR 2016)
Sep 01, 2013: Vipergen presents first discovery of small molecule IL-17A antagonists
Apr 01, 2013: Ensemble Therapeutics To Present Preclinical Data On IL-17A Inhibitors At 245th ACS National Meeting
Nov 12, 2012: Ensemble Therapeutics Presents Oral Efficacy Of Small Molecule Targeting IL-17 For Inflammation In Preclinical Studies
Oct 29, 2012: Ensemble Therapeutics To Present Poster On Interleukin-17 At 2012 ACR Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Crescendo Biologics Limited, H2 2016
Pipeline by Exicure, Inc., H2 2016
Pipeline by Novartis AG, H2 2016
Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Pipeline by UCB S.A., H2 2016
Pipeline by Vipergen ApS, H2 2016
Dormant Projects, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report